See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Baseball
Natural Disasters
Tariffs
Soccer
Tennis
Golf
NCAA
Social Media
Donald Trump
Premier League
Stock Markets
Taxes
Published • loading... • Updated

New NDA Submitted: Bysanti to Treat Acute Bipolar I and Schizophrenia

Summary by psychiatrictimes.com
Vanda Pharmaceuticals has submitted an NDA for approval of Bysanti for the treatment of acute bipolar I disorder and schizophrenia.

1 Articles

All
Left
Center
Right
psychiatrictimes.compsychiatrictimes.com

New NDA Submitted: Bysanti to Treat Acute Bipolar I and Schizophrenia

Vanda Pharmaceuticals has submitted an NDA for approval of Bysanti for the treatment of acute bipolar I disorder and schizophrenia.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

psychiatrictimes.com broke the news in on Tuesday, April 1, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal